Search results for Receptor tyrosine-protein kinase erbB-2

M802 Biosimilar – Anti-Bispecific mAb – Research Grade, ProteoGenix, PX-TA1899

Description of M802 Biosimilar - Anti-Bispecific mAb - Research Grade M802 Biosimilar – Anti-Bispecific mAb – Research Grade: A Revolutionary Treatment for Multiple Diseases The M802 Biosimilar is a groundbreaking antibody therapy that targets multiple diseases. This research grade medication is a biosimilar of the widely used anti-bispecific monoclonal antibody (mAb). It has been developed using advanced biotechnology and has shown promising results in preclinical trials. In this article, we will explore the structure, activity, and potential applications of M802 Biosimilar in the field of medicine. Structure of M802 Biosimilar M802 Biosimilar is a monoclonal antibody, which means it is a type of protein that is produced in a laboratory to mimic the antibodies naturally produced by the immune system. It is a biosimilar of the anti-bispecific mAb, which is a type of antibody that targets two different antigens simultaneously. The structure of M802 Biosimilar is similar to the anti-bispecific mAb, with some minor differences that allow it to target multiple diseases. The M802 Biosimilar is composed of two heavy chains and two light chains, which are connected by disulfide bonds. These chains are made up of amino acids, which are arranged in a specific sequence to form the unique structure of the antibody. The variable region of the antibody, which is responsible for binding to the target antigens, is highly specific and can recognize a wide range of disease-causing molecules. Activity of M802 Biosimilar The primary function of M802 Biosimilar is to bind to specific antigens and neutralize their activity. This is achieved through the binding of the variable region of the antibody to the target antigens, which prevents them from interacting with their respective receptors and causing disease. In addition to this, M802 Biosimilar also activates the immune system to eliminate the bound antigens, further enhancing its therapeutic effect. One of the key features of M802 Biosimilar is its ability to target multiple diseases at once. This is made possible by the unique structure of the antibody, which allows it to bind to multiple antigens simultaneously. This makes it a highly effective treatment for diseases that involve multiple targets, such as cancer and autoimmune disorders. Applications of M802 Biosimilar M802 Biosimilar has a wide range of potential applications in the field of medicine. Its ability to target multiple diseases makes it a versatile treatment option for a variety of conditions. Some of the potential applications of M802 Biosimilar include: Cancer: M802 Biosimilar has shown promising results in preclinical trials for the treatment of various types of cancer. Its ability to target multiple antigens makes it a highly effective treatment for tumors that have multiple mutations. Autoimmune disorders: M802 Biosimilar has the potential to treat autoimmune disorders, such as rheumatoid arthritis, by targeting the specific antigens that are responsible for the disease. Infectious diseases: The ability of M802 Biosimilar to activate the immune system makes it a potential treatment for infectious diseases, such as viral infections, by enhancing the body’s natural defense mechanisms. Other diseases: M802 Biosimilar may also have applications in the treatment of other diseases, such as cardiovascular diseases, neurodegenerative disorders, and inflammatory conditions. In conclusion, the M802 Biosimilar is a revolutionary treatment option that has the potential to target multiple diseases simultaneously. Its unique structure and activity make it a highly effective therapy with a wide range of potential applications. With further research and clinical trials, M802 Biosimilar has the potential to revolutionize the treatment of various diseases and improve the lives of patients worldwide.

HER2/ErbB2 (29D8) Rabbit Monoclonal Antibody (BSA and Azide Free)#19783, Cell Signaling Technology (CST), 19783

HER2/ErbB2 (29D8) Rabbit Monoclonal Antibody (BSA and Azide Free) detects endogenous levels of total ErbB2 protein. This antibody does not cross-react with related kinases.

HER2/ErbB2 (29D8) Rabbit Monoclonal Antibody#2165, Cell Signaling Technology (CST), 2165

HER2/ErbB2 (29D8) Rabbit Monoclonal Antibody detects endogenous levels of total ErbB2 protein. This antibody does not cross-react with related kinases.

HER2/ErbB2 (44E7) Mouse Monoclonal Antibody#2248, Cell Signaling Technology (CST), 2248

HER2/ErbB2 (44E7) Mouse Monoclonal Antibody detects transfected or over-expressed levels of HER2/ErbB2 protein. This antibody does not cross-react with any other related proteins.

HER2/ErbB2 Antibody#2242, Cell Signaling Technology (CST), 2242

HER2/ErbB2 Antibody detects endogenous levels of total ErbB2 protein. This antibody does not cross-react with related kinases.

HER2/ErbB2 (D8F12) Rabbit Monoclonal Antibody#4290, Cell Signaling Technology (CST), 4290

HER2/ErbB2 (D8F12) Rabbit Monoclonal Antibody detects endogenous levels of total HER/ErbB2 protein. This antibody may cross-react slightly with other overexpressed RTKs.

HER2/ErbB2 (M45) Antibody#3250, Cell Signaling Technology (CST), 3250

HER2/ErbB2 (M45) Antibody detects endogeneous levels of total ErbB2 protein. This antibody does not cross-react with related kinases.

HER2 (Trastuzumab Biosimilar) Human Monoclonal Antibody#10583, Cell Signaling Technology (CST), 10583

HER2 (Trastuzumab Biosimilar) Human mAb was confirmed to bind to its intended target protein HER2 using flow cytometry.

Research Grade Anti-4-1BB & HER2 Bispecific Antibody (Yh32367) (HC336216), abinScience, HC336216

Research Grade M802 (HY286136), abinScience, HY286136